{
    "clinical_study": {
        "@rank": "70680", 
        "arm_group": {
            "arm_group_label": "Patient self-administered insulin", 
            "arm_group_type": "Experimental", 
            "description": "The study's only arm"
        }, 
        "brief_summary": {
            "textblock": "This study will examine the feasibility of implementing a clinician-supported patient\n      self-managed inpatient insulin intervention. It will: assess the number of eligible patients\n      presenting over time; assess patients' willingness to enroll; assess patients' ability to\n      successfully complete the intervention; examine occurrences of hyperglycemia and\n      hypoglycemia; and assess patients' satisfaction with inpatient diabetes care."
        }, 
        "brief_title": "Pilot Study of Clinician-supported Patient Self-management of Hospital Insulin Therapy", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": "Diabetes Mellitus"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Admitted to the Hospital of the University of Pennsylvania (HUP) in the past 72\n             hours.\n\n          -  Current HUP location is either Founders 12 or Founders 14.\n\n          -  Age 18 years or older.\n\n          -  Type-1 or type-2 diabetes mellitus requiring home basal-bolus insulin therapy\n             administered via subcutaneous injection (not pump).\n\n          -  Patient manages own basal-bolus insulin therapy at home without assistance, including\n             measuring own blood glucose (at least at mealtimes) and administering own\n             subcutaneous insulin.\n\n          -  Patient is willing to use the following insulin products: rapid-acting insulin aspart\n             via insulin pen (NovoLog) and long-acting insulin glargine via vial and syringe\n             (Lantus).\n\n          -  Most recent hemoglobin A1c was measured within past 6 months and was <7.5%.\n\n          -  Active order for in-hospital basal-bolus or sliding-scale insulin.\n\n          -  Patient is willing and able to record their self-measured blood glucose results,\n             doses of insulin that they self-administer, a food journal, and exercise log.\n\n          -  Clinical care team agrees with study inclusion.\n\n        Exclusion Criteria:\n\n          -  Inpatient order for insulin via subcutaneous infusion (i.e., pump) or intravenous\n             infusion (i.e., drip).\n\n          -  Inability to perform the activities required by the trial.\n\n          -  Primary reason for admission was hyperglycemia, hypoglycemia, diabetic ketoacidosis,\n             hyperglycemic hyperosmolar nonketotic coma, a psychiatric condition, acute alcohol\n             poisoning, or acute drug ingestion.\n\n          -  Order for a newly-prescribed or increased dose of a previously-prescribed\n             corticosteroid.\n\n          -  Enteral or parenteral nutrition.\n\n          -  Expected length of stay <48h, as determined by treating physician.\n\n          -  At risk for self-harm, as determined by 1-to-1 status placement.\n\n          -  Pregnant, as recorded on medical record.\n\n          -  Cannot understand, speak, and read English.\n\n          -  Patient does not wish to utilize Novolog and Lantus while in the hospital.\n\n          -  Prior enrollment in this trial.\n\n          -  Do not resuscitate status.\n\n          -  Inability to give written informed consent.\n\n          -  Clinical care team disagrees with study inclusion.\n\n          -  Patient has limited mobility such that they cannot safely access the bedside\n             medication lockbox."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02144441", 
            "org_study_id": "819840"
        }, 
        "intervention": {
            "arm_group_label": "Patient self-administered insulin", 
            "description": "Inpatient will administer hospital-dispensed basal-bolus insulin (glargine and aspart)  according to a regimen developed in collaboration with the diabetes consult service.", 
            "intervention_name": "glargine and aspart", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Glargine", 
                "Insulin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Diabetes Mellitus", 
            "Insulin", 
            "Self Administration", 
            "Patient Satisfaction", 
            "Glucose", 
            "Hypoglycemia", 
            "Hyperglycemia"
        ], 
        "lastchanged_date": "May 19, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Philadelphia", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "19104"
                }, 
                "name": "Hospital of the University of Pennsylvania"
            }, 
            "investigator": {
                "last_name": "Sean Hennessy, PharmD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Proof-of-concept Trial of Clinician-supported Patient Self-management of Hospital Insulin Therapy", 
        "overall_contact": {
            "email": "celeonar@mail.med.upenn.edu", 
            "last_name": "Charles E Leonard, PharmD, MSCE", 
            "phone": "215-573-2663"
        }, 
        "overall_official": {
            "affiliation": "Perelman School of Medicine at the University of Pennsylvania", 
            "last_name": "Sean Hennessy, PharmD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Trial feasibility metric: number of screened patients", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "Trial feasibility metric: number of eligible patients", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "Trial feasibility metric: number of patients approached for consent", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "Trial feasibility metric: proportion of eligible patients not consenting", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "Trial feasibility metric: reasons for non-consent", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "To examine baseline demographics and clinical factors, such as: mean age, median age, proportion female sex, other demographics, proportion with type I diabetes, proportion with type II diabetes, hemoglobin A1c on admission, reasons for admission", 
                "measure": "Trial feasibility metric: characteristics of consenting subjects and non-consenting patients", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "Trial feasibility metric: proportion of enrolled subjects completing the intervention", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "Trial feasibility metric: proportion of enrolled subjects disenrolling", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "Trial feasibility metric: reasons for disenrollment", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02144441"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Frequency of blood glucose concentrations that are hyperglycemic (> 180 mg/dL)", 
                "measure": "Hyperglycemia", 
                "safety_issue": "No", 
                "time_frame": "During hospitalization (maximum length 7 days)"
            }, 
            {
                "description": "Satisfaction with inpatient diabetes care, as measured by the Diabetes Treatment Satisfaction Questionnaire for Inpatients (DTSQ-IP) adapted for use in the United States", 
                "measure": "Patient satisfaction", 
                "safety_issue": "No", 
                "time_frame": "At the end of hospitalization (maximum length 7 days)"
            }, 
            {
                "description": "Frequency of hypoglycemia (blood glucose concentration < 70 mg/dL) and frequency of severe hypoglycemia (blood glucose concentration < 40 mg/dL)", 
                "measure": "Hypoglycemia", 
                "safety_issue": "Yes", 
                "time_frame": "During hospitalization (maximum length 7 days)"
            }
        ], 
        "source": "University of Pennsylvania", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Pennsylvania", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}